RPS19

Across TCGA pan-cancer cohorts, RPS19 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPS19 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPS19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS19 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

GBM, HNSC, and COAD are the cancer types where RPS19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.254	0.541	.001	22	view →
HNSC	DFS	Tertile	All	1.000	0.310	.011	20	view →
COAD	DFS	Median	III,IV	1.000	0.891	.032	12	view →
CCRCC	DFS	Tertile	All	0.610	0.850	.006	10	view →
PDAC	DFS	Tertile	III,IV	0.216	0.600	.011	6	view →
LSCC	DFS	Median	III,IV	0.447	0.781	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPS19–GBM (DFS)

Open the GBM breakdown →